Promising Tools for Personalized Chemotherapy in Non-Small Cell Lung Cancer

Strategic Insights -

Researchers in Vancouver, Canada, have made significant progress in developing personalized chemotherapy for non-small cell lung cancer (NSCLC) patients. Their study, published in Clinical Cancer Research, presents promising data on patient-derived first-generation xenografts as tools for predicting drug responses. This breakthrough has the potential to revolutionize the treatment of NSCLC, a disease with limited treatment options.

Key Takeaways:

  • The study used first-generation subrenal capsule xenografts of primary NSCLCs from 32 patients to determine responses to conventional chemotherapeutic regimens.
  • The researchers treated the xenografts with four different regimens: cisplatin+vinorelbine, cisplatin+docetaxel, cisplatin+gemcitabine, and evaluated their effectiveness.
  • The study found that the xenografts were effective in predicting responses to chemotherapy, with 70% of patients showing positive responses to at least one treatment regimen.
  • The researchers concluded that these patient-derived xenografts hold promise for application in personalized chemotherapy of NSCLC patients.

Statistics:

  • 32 patient-derived NSCLC samples were used in the study.
  • 4 different chemotherapeutic regimens were tested: cisplatin+vinorelbine, cisplatin+docetaxel, cisplatin+gemcitabine.
  • 70% of patients showed positive responses to at least one treatment regimen.
  • The study was published in Clinical Cancer Research, a peer-reviewed journal.

Sources:

  • Dong, X., et al. (2010). Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clinical Cancer Research, 16(5), 1442-51.
  • American Association Cancer Research. Contacts: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.
  • University of British Columbia. Department of Cancer Endocrinology. BC Cancer Agency. Vancouver, British Columbia, Canada.